High PKCα activity, high netrin-1 expression, and low UNC5B expression enhanced the tolerance of bladder cancer cells to cisplatin, whereas the opposite expression pattern increased their sensitivity to cisplatin treatment [16]. Here, PRKCA is linked to urinary bladder cancer.